CA-BIOCELL-TECHNOLOGY
13.6.2019 02:53:04 CEST | Business Wire | Press release
BioCell Technology, LLC, a branded dietary ingredient supplier, today announced the presentation of The Effects of Skin Aging Associated with the Use of BioCell Collagen® in Healthy Adult Females: A Randomized, Double-blind, Placebo-controlled Clinical Trial . These results were presented in a poster session at the American Society for Nutrition (ASN) Nutrition 2019 on June 9, 2019, and are available at http://bit.ly/2WzhODi . This poster will be published as part of the proceedings of Nutrition 2019 by ASN. The manuscript of the study will be published in the online and print versions of the peer review journal Alternative Therapies in Health and Medicine (ATHM).
The goal of the study was to determine if a correlation existed between the effects of the dietary supplement, BioCell-Collagen®, with changes associated with skin aging. The study was a 128-female subject, 12-week, double-blind, placebo-controlled trial. Participants were randomly assigned to an intervention or a placebo. The intervention consisted of twice daily 500mg oral administration of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract dietary ingredient composed of a naturally-occurring matrix of collagen type-II peptides (≥300 mg), chondroitin sulfate (≥100 mg), and hyaluronic acid (≥50 mg).
For the 113 participants completing the study, BioCell Collagen® supplementation compared to a placebo resulted in:
- Significantly reduced facial lines and wrinkles (P = .019) and crow’s feet lines and wrinkles (P = .05)
- Increased skin elasticity (P = .008) and cutaneous collagen content (P < .001) by 12%
- Improved indicators associated with a more youthful skin appearance based on visual grading and wrinkle width (P = .046)
- Decreased skin dryness and erythema.
- No difference existed between the supplement and the placebo for skin surface water content or retention. The supplement was well tolerated, with no reported adverse reactions.
“We are very excited to publish the findings of our largest study to date, which further supports the efficacy of our flagship dietary ingredient BioCell Collagen®. Human clinical studies continue to be the gold standard for substantiating dietary supplement claims and we take pride that our licensed partners can take advantage,” said Suhail Ishaq, president of BioCell Technology.
The latest study validates an earlier pilot study that demonstrated similar results- Schwartz SR, Park J. Ingestion of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract; enhanced blood microcirculation and reduced facial aging signs. Clin Interven Aging . 2012; 7: 267-273.
“An impressive example of how a series of studies, capped by a randomized, double-blind, placebo-controlled, supports a ‘beauty from within’ claim in healthy women. Even more impressive was that the results remained statistically significant even after an intention-to-treat analysis was performed that included the few subjects that dropped out of the study. Such an analysis is seen in only about 15-20% of randomized, placebo-controlled blinded clinical studies published in leading medical journals,” said Alexander Schauss, PhD, FACN, CFS, Senior Director of Research at AIBMR Life Sciences, and the corresponding author.
“It is important that the supplement industry conducts research at the pinnacle of good science and this includes a double blind, properly populated study like this one,” said Stephen Schwartz, President and CEO of International Research Services, Inc.
About BioCell Collagen ®
BioCell Collagen® is a clinically tested branded dietary ingredient that promotes active joints, youthful-looking skin, and healthy connective tissues. BioCell Collagen® contains a patented composition of naturally occurring hydrolyzed collagen type II peptides, chondroitin sulfate and hyaluronic acid in a highly absorbable matrix form that has been the subject of numerous human clinical trials, including trials on safety, efficacy, and bioavailability. BioCell Collagen® is self-affirmed GRAS (Generally Recognized As Safe). BioCell Collagen® is non-GMO and free of gluten, soy, shellfish, fish, egg, milk, peanuts and sugar. BioCell Collagen® is made exclusively in the USA and Europe. For more information, visit www.BioCellCollagen.com .
About BioCell Technology, LLC
BioCell Technology is a research, product development, branding, and marketing company that manufactures innovative, science-based ingredients that have applications in dietary supplements, functional foods and cosmetics. The company licenses its branded ingredients to leading consumer packaged goods companies for use in their finished products. For more information visit www.BioCellTechnology.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005972/en/
Contact:
Suhail Ishaq President of BioCell Technology, LLC 714-632-1231
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Digital Trust Index 2026: AI Skepticism and Identity Access Friction Are Costing Revenue31.3.2026 14:00:00 CEST | Press release
93% of IT leaders are deploying GenAI, but only 23% of consumers trust companies that use AI to handle their data. Friction at sign-up, login, and onboarding is causing customer abandonment and revenue loss, with 68% of consumers switching due to website issues. 69% of consumers trust companies more when MFA (multi factor authentication) is used, 68% say the same about passkeys. Thales today released the 2026 Digital Trust Index, one of the most comprehensive global studies of digital trust. Surveying more than 15,000 consumers, business partners, and IT decision makers across 13 industries, the research reveals that digital trust is won or lost during sign-up, login, and throughout the lifecycle of personal data handling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331668723/en/ Beyond banking’s clear lead, the rest of the sectors fall well behind in consumer confidence. ©Thales Consumer Trust is Won or Lost at Login
Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients31.3.2026 14:00:00 CEST | Press release
Tanner Pharma Group, a global provider of specialty medicine access solutions, and Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products for gastrointestinal cancers, have announced a strategic partnership to enable global access to eRapa for patients with Familial Adenomatous Polyposis (FAP) through an Early Access / Named Patient Program. FAP is characterized by a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option, and surgical resection remains the standard of care. eRapa is a proprietary oral capsule formulation of rapamycin (sirolimus), an mTOR inhibitor involved in cellular metabolism, growth, and proliferation and activated during tumorigenesis. mTOR has been shown to be over-expressed in FAP polyps, supporting the rationale for its use in treatment. Through this collaboration, Tanner Pharma will facilitate compliant, controlled access to eRapa
SLB and Azule Energy Scale Enterprise Digital Operations to Strengthen Energy Delivery in Angola31.3.2026 14:00:00 CEST | Press release
SLB’s enterprise digital platform will enhance execution reliability across Azule’s operations in Angola Global technology company SLB (NYSE: SLB) today announced a three-year agreement with Azule Energy to continue and expand the use of its enterprise digital platform across Azule’s operations in Angola. The platform will help Azule drive more consistent execution, accelerate decision-making, and support reliable energy delivery across its portfolio. Azule Energy — a joint venture of bp and Eni and the largest independent energy producer in Angola — operates some of the region’s most complex assets. The agreement builds on two years of Delfi™ use within Azule’s reservoir organization, where the platform supports reservoir studies, modelling, simulation, and well planning workflows, and supports enterprise-scale digital integration by connecting reservoir workflows with broader operational data environments over time. “Azule operates large, complex energy assets where execution reliabi
Esri and RoboGarden Sign Strategic MOU to Advance Geospatial and Geomatics Education31.3.2026 14:00:00 CEST | Press release
Agreement Explores New Models for Digital Learning, Academic Collaboration, and Global Workforce Readiness Esri and RoboGarden have signed an MOU to explore strategic collaboration that broadens access to modern GIS and geomatics education. RoboGarden, a Canadian EdTech company, offers gamified and scalable digital learning solutions for academic institutions, governments, and industry. The MOU outlines joint exploration of academic pathways, improved regional coordination, and potential creation of a Geospatial & Geomatics Virtual Academy. The agreement focuses on enhancing digital learning delivery, expanding localized e-learning opportunities, and supporting global workforce development in high-demand technology fields. To stay informed about Esri’s education initiatives and resources, visit esri.com/en-us/industries/education/overview. Esri, the global leader in geographic information system (GIS) technology, today announced the signing of a Memorandum of Understanding (MOU) with R
ExaGrid Named a Finalist for the Network Computing Awards 202631.3.2026 14:00:00 CEST | Press release
ExaGrid nominated in 11 Categories for annual industry awards ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in 11 categories for the annual Network Computing Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331887370/en/ ExaGrid has become a finalist in the following categories: Data Protection Product of the Year The Return On Investment Award Air Gapped Ransomware Recovery Product of the Year Storage Product of the Year Hardware Product of the Year The Customer Service Award Enterprise Product of the Year New Product of the Year Product of the Year Company of the Year Additionally, ExaGrid is nominated for the “Bench Tested Product of the Year” award determined by judges after an independent product review of the ExaGrid Tiered
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
